Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Merck of Germany Considers Entry into Japanese Biosimilars Market
June 18, 2012
- Pharmacists Predict Further Use of Mucosta Generics: Survey
June 18, 2012
- Asklep to Establish Subsidiary in Taiwan, Buffing Up CRO Business in Asia
June 15, 2012
- Antiallergic Agent S-555739 Shows Efficacy in Combination Therapy in PIIb Study: Shionogi
June 15, 2012
- Sales of Januvia, Cervarix Exceed 50 Billion Yen in 2 Years since Launch
June 15, 2012
- DPP-4 Inhibitors Surged, RA Treatments Maintained Strong Growth in FY2011
June 15, 2012
- Top 100 Products in FY2011: Pronounced Growth for ARB Combinations with Declining Sales of Monodrugs
June 15, 2012
- Sanofi, Hisamitsu to Form JV for Allergy-Related OTCs, Seen Eyeing Allegra OTC Launch
June 14, 2012
- Janssen Pharmaceutical to Enlarge Plant Expecting 2.7 Times Current Shipping Volume
June 14, 2012
- Astellas to Collaborate with DNDi on Drug Discovery for Tropical Diseases
June 14, 2012
- MTPC to Launch Tenelia in Sept., Expecting to Become a Growth Driver: President Tsuchiya
June 14, 2012
- Midazolam is Most Used Sedative in Terminal Care: Doctor Survey
June 13, 2012
- Japan Vaccine to Develop, Supply All Vaccines Needed in Japan by 2020
June 13, 2012
- Astellas Launches Dificlir in Europe
June 13, 2012
- Sanofi-Aventis Files NDA for GLP-1 Receptor Agonist Lixisenatide in Japan
June 13, 2012
- Daiichi Sankyo Launches Olmesartan in Mexico
June 12, 2012
- Astellas Completes Enrollment for Global PIII Trial for MDV3100
June 12, 2012
- Sawai Considers Leveraging “MSs with MR Qualifications” with Medipal Group
June 12, 2012
- DSP Aims to Boost Latuda Sales with Add’l Indication of Bipolar Depression in US: President Tada
June 12, 2012
- IPV More Than Double Normal Cost for Japanese Market: Sanofi Pasteur
June 11, 2012
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…